Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2001 to 2050 of 3765 results for treatment

  1. Thrombin injections for pseudoaneurysms (IPG60)

    Evidence-based recommendations on thrombin injections for pseudoaneurysms. This involves injecting thrombin into the pseudoaneurysm. The aim is to form a small clot to plug the ‘hole’ in the artery.

  2. Radiofrequency ablation for symptomatic interdigital (Morton's) neuroma (IPG539)

    Evidence-based recommendations on radiofrequency ablation for symptomatic interdigital (Morton’s) neuroma. This involves using pulses of radiofrequency heat energy to damage the nerve, with the aim of reducing pain.

  3. Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]

    Discontinued Reference number: GID-TA10933

  4. iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)

    NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .

  5. ADXBLADDER for detecting bladder cancer (MIB180)

    NICE has developed a medtech innovation briefing (MIB) on ADXBLADDER for detecting bladder cancer .

  6. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206)

    This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.

  7. Axonics sacral neuromodulation system for faecal incontinence (MIB259)

    NICE has developed a medtech innovation briefing (MIB) on Axonics sacral neuromodulation system for faecal incontinence .

  8. Percutaneous radiofrequency ablation for primary or secondary lung cancers (IPG372)

    Evidence-based recommendations on percutaneous radiofrequency ablation for primary or secondary lung cancers. This involves inserting 1 or more electrodes (needle-like probes) through the chest into the lung and using an electrical current to produce heat to destroy the cancer cells.

  9. Cardiovascular disease prevention: cardiovascular risk assessment for people with bipolar, schizophrenia or other psychoses (IND150)

    This indicator covers the percentage of patients aged between 25 and 84 years with schizophrenia, bipolar affective disorder and other psychoses (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes) who have had a full formal cardiovascular disease risk assessment performed in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM120

  10. Cancer: 3-month review (IND113)

    This indicator covers the percentage of patients with cancer diagnosed within the preceding 15 months who have a review recorded as occurring within 3 months of the practice receiving confirmation of the diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM62

  11. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    Discontinued Reference number: GID-TA11000

  12. Mini/micro screw implantation for orthodontic anchorage (IPG238)

    Evidence-based recommendations on mini/micro screw implantation for orthodontic anchorage. This involves inserting small screws into the jaw bone to create anchors that support tooth realignment.

  13. Laparoscopic repair of abdominal aortic aneurysm (IPG229)

    Evidence-based recommendations on laparoscopic repair of abdominal aortic aneurysm. This involves replacing the damaged parts of the aorta with an artificial piece of blood vessel, performed through small cuts in the abdomen (keyhole surgery).

  14. Laparoscopic laser myomectomy (IPG23)

    Evidence-based recommendations on laparoscopic laser myomectomy. This involves passing a fine telescope (laparascope) through small cuts in the abdomen and uterus wall, and using a laser to destroy the fibroids.

  15. Therapeutic sialendoscopy (IPG218)

    Evidence-based recommendations on therapeutic sialendoscopy. This involves using a flexible tube to enter the salivary gland, and visualise and remove the stone.

  16. Transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain (IPG632)

    Evidence-based recommendations on transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain in adults. This involves delivering focused ultrasound to a small part of the brain (in the thalamus) responsible for transmitting pain signals to destroy it.

  17. Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333]

    Discontinued Reference number: GID-TAG418

  18. NICE recommends that a new model for multiple sclerosis is developed, ideally based on UK patient cohorts, which uses the best available evidence (including experience to date from the risk-sharing scheme) and includes all currently available treatments.

    date from the risk-sharing scheme) and includes all currently available treatments. Any explanatory notes(if applicable) None. Source...

  19. Percutaneous coblation of the intervertebral disc for low back pain and sciatica (IPG543)

    Evidence-based recommendations on percutaneous coblation of the intervertebral disc for low back pain and sciatica. This involves using heat from an electrode to destroy the tissue.

  20. Lung volume reduction surgery for advanced emphysema (IPG114)

    Evidence-based recommendations on lung volume reduction surgery for treating advanced emphysema. This involves removing damaged lung tissue using a special stapling device, a laser, or both.

  21. Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (MIB137)

    NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .

  22. Rehabilitation for chronic neurological disorders including acquired brain injury (NG252)

    This guideline covers rehabilitation in all settings for children, young people and adults with a chronic neurological disorder, neurological impairment or disabling neurological symptoms due to acquired brain injury, acquired spinal cord injury, acquired peripheral nerve disorder, functional neurological disorder or progressive neurological disease.

  23. Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism (IPG778)

    Evidence-based recommendations on percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism. This involves removing the clot through a catheter inserted into a vein.

  24. Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (IPG805)

    Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.

  25. Irreversible electroporation for treating renal cancer (IPG443)

    Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.

  26. Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]

    In development Reference number: GID-TA10994 Expected publication date: TBC

  27. Percutaneous transluminal renal sympathetic denervation for resistant hypertension (IPG754)

    Evidence-based recommendations on percutaneous transluminal renal sympathetic denervation for resistant hypertension. This involves inserting a device through the skin (percutaneous) into an artery in the thigh and then into the renal arteries (transluminal). It sends radio or sound waves to destroy the nerves in the renal arteries (sympathetic denervation). The aim is to lower blood pressure.

  28. Preoperative high dose rate brachytherapy for rectal cancer (IPG531)

    Evidence-based recommendations on preoperative high dose rate brachytherapy for rectal cancers. This involves inserting an applicator into the rectum and using it to deliver radiation to the tumour.

  29. Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults (IPG634)

    Evidence-based recommendations on transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults. This involves electrically stimulating nerves in the throat or neck, while the person swallows. The aim is to strengthen the muscles involved in swallowing.

  30. Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver (IPG786)

    Evidence-based recommendations on selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver. This involves injecting tiny radioactive spheres into the blood vessels that supply the liver metastases.

  31. Artificial intelligence for analysing CT brain scans (MIB207)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .

  32. High-intensity focused ultrasound for symptomatic breast fibroadenoma (IPG592)

    Evidence-based recommendations on high-intensity focused ultrasound for symptomatic breast fibroadenoma in adults. This involves using high-frequency sound waves to heat up the tissues in the lump.

  33. Endoscopic ablation for an anal fistula (IPG645)

    Evidence-based recommendations on endoscopic ablation for an anal fistula in adults. This involves applying heat to the fistula.

  34. Photodynamic therapy for advanced bronchial carcinoma (IPG87)

    Evidence-based recommendations on photodynamic therapy for advanced bronchial carcinoma. This involves giving the patient something that makes them sensitive to light, then using special equipment to shine light onto the cancer to activate the substance and destroy some of the cancer.

  35. WoundExpress to manage lower leg wounds (MIB261)

    NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .

  36. Galaxy UNYCO for temporary stabilisation of lower limb fractures (MIB166)

    NICE has developed a medtech innovation briefing (MIB) on Galaxy UNYCO for temporary stabilisation of lower limb fractures .

  37. Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules (IPG562)

    Evidence-based recommendations on ultrasound-guided percutaneous radiofrequency ablation for treating benign thyroid nodules in adults. This involves using heat energy to destroy tissue in the nodules.

  38. Trabeculotomy ab interno for open angle glaucoma (IPG397)

    Evidence-based recommendations on trabeculotomy ab interno for open angle glaucoma. This involves using a specifically designed surgical instrument to remove a portion of tissue, with the aim of improving the eye’s drainage pathway.

  39. Liposuction for chronic lipoedema (IPG721)

    Evidence-based recommendations on liposuction for chronic lipoedema in adults. This involves using suction to remove abnormal fat.

  40. QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography (HTG571)

    Evidence-based recommendations on QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography.

  41. Liposuction for chronic lymphoedema (IPG723)

    Evidence-based recommendations on liposuction for chronic lymphoedema in adults. This involves using suction to remove fluid and fat through punctures in the skin.

  42. Research recommendations process and methods guide (PMG45)

    This process and methods guide has been developed to help guidance‑producing centres make research recommendations. It describes a step-by-step approach to identifying uncertainties, formulating research recommendations and research questions, prioritising them and communicating them to the NICE Science Policy and Research (SP&R) team, researchers, and funders

  43. Coeliac disease (QS134)

    This quality standard covers recognising, assessing and managing coeliac disease in adults, young people and children. It describes high-quality care in priority areas for improvement.

  44. Transition between inpatient hospital settings and community or care home settings for adults with social care needs (QS136)

    This quality standard covers admissions into, and discharge from, inpatient hospital settings for adults (aged 18 years and over) with social care needs. It describes high-quality care in priority areas for improvement.

  45. Cryotherapy for chronic rhinitis (IPG771)

    Evidence-based recommendations on cryotherapy for chronic rhinitis. This involves destroying a nerve in the nose to reduce chronic rhinitis symptoms.

  46. Lipid disorders: FH assessment and diagnosis (historical readings) (IND260)

    This indicator covers the percentage of patients with a total cholesterol reading greater than 7.5 mmol/litre when aged 29 years or under, or greater than 9.0 mmol/litre when aged 30 years or over, who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM244

  47. Photodynamic therapy for early-stage oesophageal cancer (IPG200)

    Evidence-based recommendations on photodynamic therapy for early-stage oesophageal cancer. This involves injecting a photosensitising agent into the tumour which is then activated by a light to destroy the tumour cells.